Drug combinations and all cause mortality in heart disease: Dosages and types of ACE inhibitors need to be known

doi:10.1136/bmj.331.7509.159-b

From trainee to consultant, BMJ Group offers doctors around the world tailored information, special events, learning resources and recruitment services at every step along their career path.

... by doctors, for doctors, for patients
We are open for entries!

Online learning

BMJ Learning

High-quality CME / CPD for doctors and other healthcare professionals. BMJ Learning features hundreds of accredited, peer-reviewed learning modules in text, video, and audio formats. Find out more

Courses and Qualifications

BMJ Masterclasses

BMJ Masterclasses, led by experts, help clinicians to use the latest evidence and recent guidelines in practice and meet their CPD/CME requirements. Find out more

Exam Preparation

The leading provider of online exam preparation, helping over 167,000 healthcare professionals to pass their exams. Find out more

onExamination

Search all BMJ comment articles:

From

Limit by

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

Frank A Snyder, physician (slude1@aol.com)

Wilmington Internal Medicine 2215 Canterwood, Wilmington, NC 28401, USA

EDITOR—The study reported by Hippisley-Cox and Coupland leads to much generalisation.1 Firstly, I am concerned that the data on angiotensin converting enzyme (ACE) inhibitors, contradict convention. Secondly, without actual data in front of me, I have to guess at the meaning of the ACE inhibitor data.

As the EUROPA, PROGRESS, ANBP, PEACE, TRACE, SAVE, and …